CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome

With the advent of anti-β-amyloid therapies, clinical distinction between Aβ + and Aβ- in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays. Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q),...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neurology 2024-08, Vol.15, p.1422681
Main Authors: Lahiri, Durjoy, Seixas-Lima, Bruna, Roncero, Carlos, Verhoeff, Nicolaas Paul, Freedman, Morris, Al-Shamaa, Sarmad, Chertkow, Howard
Format: Article
Language:English
Subjects:
Alzheimer
amyloid-beta
CAPS
clinical
early diagnosis
Neurology
predictivity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the advent of anti-β-amyloid therapies, clinical distinction between Aβ + and Aβ- in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays. Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q), and imaging characteristics were collected from 52 subjects with possible/probable AD. Participants with Aβ+ status had lower baseline MMSE scores (24.50 vs. 26.85,  = 0.009) and higher total NPI-Q scores (2.73 vs. 1.18,  
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2024.1422681